KRAS and intestinal neoplasm: Although the MC38 model used here is highly immunogenic and may not fully represent non-inflamed human CRCs, the efficacy of the APC11 peptide was also confirmed in two genetically engineered mouse models of APC loss — orthotopically transplanted AKP organoids (carrying Apc/Kras/p53 mutations) and ApcMin/+ spontaneous intestinal tumors.